HIV fusion and its inhibition in antiretroviral therapy

Reviews in Medical Virology

Volumn 14, Issue 5, 2004, Pages 321-337

  Greenberg, Michael ^a   Cammack, Nick ^b   Salgo, Miklos ^c   Smiley, Lynn ^a  

^a Trimeris Inc   (United States)

^b Roche   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); ABACAVIR; AMD 070; AMINO ACID; AMPRENAVIR; ANTIRETROVIRUS AGENT; CAFFEINE; CD4 ANTIGEN; CD4 IMMUNOGLOBULIN G2; CHEMOKINE RECEPTOR; CHLORZOXAZONE; CREATININE; DAPSONE; DEBRISOQUINE; EFAVIRENZ; ENFUVIRTIDE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; INTEGRASE INHIBITOR; LEUCINE ZIPPER PROTEIN; MARAVIROC; MEPHENYTOIN; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TNX 355; UNCLASSIFIED DRUG; UNINDEXED DRUG; V 165; VICRIVIROC;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AREA UNDER THE CURVE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; EYELID EDEMA; FACE EDEMA; FATIGUE; FEVER; GENOTYPE; GLOMERULONEPHRITIS; GUILLAIN BARRE SYNDROME; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNE COMPLEX DISEASE; INFECTION; INJECTION PAIN; MAJOR CLINICAL STUDY; MOUTH DISEASE; NAUSEA; NONHUMAN; PARALYSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRESCHOOL CHILD; PROGNOSIS; RASH; RESPIRATORY DISTRESS; REVIEW; SCHOOL CHILD; SKIN CYST; SKIN INDURATION; SKIN MANIFESTATION; SKIN NODULE; VIRUS INHIBITION; VOMITING;

ADOLESCENT; CHILD; CLINICAL TRIALS, PHASE III; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MEMBRANE FUSION; PEPTIDE FRAGMENTS; TREATMENT OUTCOME;

EID: 4544381403     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.440     Document Type: Review

References (109)

1. Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-860.
2. Kosel BW, Aweeka F. Drug interactions of antiretroviral agents. In AIDS Clinical Review, Volberding PA, Jacobsen MA (eds). Marcel Dekker: New York, 2003; 193-227.
3. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001; 358: 1322-1327.
4. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002; 288: 222-235.
5. Shafer RW, Winters MA, Palmer S, et al. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med 1998; 128: 906-911.
6. Nair V. HIV integrase as a target for antiviral chemotherapy. Rev Med Virol 2002; 12: 179-193.
7. Donzella GA, Schols D, Lin SW, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998; 4: 72-77.
8. Guo Q, Ho HT, Dicker I, et al. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J Virol 2003; 77: 10528-10536.
9. Hendrix CW, Flexner C, MacFarland RT, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000; 44: 1667-1673.
10. Jacobson JM, Lowy I, Fletcher CV, et al. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J Infect Dis 2000; 182: 326-329.
11. O'Brien WA, Chen IS, Ho DD, et al. Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4. J Virol 1992; 66: 3125-3130.
12. Schacker T, Collier AC, Coombs R, et al. Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9: 145-152.
13. Schols D, Claes S, Hatse S, et al. Anti-HIV activity of AMD070, an orally bioavailable CXCR4 antagonist H. In 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA, 10-14 February 2003; Abstract 563.
14. Schooley RT, Merigan TC, Gaut P, et al. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med 1990; 112: 247-253.
15. Strizki JM, Xu S, Wagner NE, et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98: 12718-12723.
16. Wang T, Zhang Z, Wallace OB, et al. Discovery of 4-benzoyl-1-[(4-methoxy- 1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J Med Chem 2003; 46: 4236-4239.
17. Wild CT, Shugars DC, Greenwell TK, et al. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994; 91: 9770-9774.
18. Earl PL, Doms RW, Moss B. Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci USA 1990; 87: 648-652.
19. Stamatatos L, Cheng-Mayer C. Evidence that the structural conformation of envelope gp120 affects human immunodeficiency virus type 1 infectivity, host range, and syncytium-forming ability. J Virol 1993; 67: 5635-5639.
20. Gallaher WR. Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus. Cell 1987; 50: 327-328.
21. Gallaher WR, Ball JM, Carry RF, et al. A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res Hum Retroviruses 1989; 5: 431-440.
22. Delwart EL, Mosialos G, Gilmore T. Retroviral envelope glycoproteins contain a 'leucine zipper'-like repeat. AIDS Res Hum Retroviruses 1990; 6: 703-706.
23. Weissenhorn W, Dessen A, Harrison SC, et al. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997; 387: 426-430.
24. Sullivan N, Sun Y, Sattentau Q, et al. CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J Virol 1998; 72: 4694-4703.
25. Berson JF, Long D, Doranz BJ, et al. A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J Virol 1996; 70: 6288-6295.
26. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381: 661-666.
27. Feng Y, Broder CC, Kennedy PE, et al. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272: 872-877.
28. LaBranche CC, Huffman TL, Romano J, et al. Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity. J Virol 1999; 73: 10310-10319.
29. LaBranche CC, Galasso G, Moore JP, et al. HIV fusion and its inhibition. Antiviral Res 2001; 50: 95-115.
30. Bullough PA, Hughson FM, Skehel JJ, et al. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 1994; 371: 37-43.
31. Carr CM, Kim PS. A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell 1993; 73: 823-832.
32. Chen CH, Matthews TJ, McDanal CB, et al. A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J Virol 1995; 69: 3771-3777.
33. Lu M, Blacklow SC, Kim PS. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995; 2: 1075-1082.
34. Melikyan GB, Markosyan RM, Hemmati H, et al. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 2000; 151: 413-423.
35. Munoz-Barroso I, Salzwedel K, Hunter E, et al. Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J Virol 1999; 73: 6089-6092.
36. Furuta RA, Wild CT, Weng Y, et al. Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol 1998; 5: 276-279.
37. Meaden ER, Hoggard PG, Newton P, et al. P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. J Antimicrob Chemother 2002; 50: 583-588.
38. Jones K, Bray PG, Khoo SH, et al. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? AIDS 2001; 15: 1353-1358.
39. Turriziani O, Schuetz JD, Pocher F, et al. Impaired 2′,3′- dideoxy-3′-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrug resistant protein 4 with a possible role for ATP-binding cassette C11. Biochem J 2002; 368: 325-332.
40. Schuetz JD, Connelly MC, Sun D, et al. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999; 5: 1048-1051.
41. Williams GC, Liu A, Knipp G, et al. Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother 2002; 46: 3456-3462.
42. Moore JP, McKeating JA, Huang YX, et al. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J Virol 1992; 66: 235-243.
43. Collier AC, Coombs RW, Katzenstein D, et al. Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10: 150-156.
44. Hodges TL, Kahn JO, Kaplan LD, et al. Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex. Antimicrob Agents Chemother 1991; 35: 2580-2586.
45. Meng TC, Fischl MA, Cheeseman SH, et al. Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8: 152-160.
46. Kuritzkes DR, Jacobson J, Powderly WG, et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004; 189: 286-291.
47. Reynes J, Rouzier R, Kanouni T, et al. SCH C: Safety and antiviral effects of a CCR5 receptor antagonist in HIV-1-infected subjects. In 9th Conference on Retroviruses and Opportunistic Infections, Seattle, USA, 24-28 February 2003; Abstract 1.
48. Schurmann D, Rouzier R, Nougarede R, et al. SCH D: Antiviral activity of a CCR5 receptor antagonist. In 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA, 8-11 February 2004; Abstract 140LB.
49. Pozniak AL, Fatkenheuer G, Johnson M, et al. Effect of short term monotherapy with UK-427,857 on viral load in HIV-infected patients. In 43rd Interscience Conference on Antiviral Agents and Chemotherapy, Chicago, USA, 14-17 September 2003; Abstract H-443.
50. Russel D, Bakhtyari A, Jazawi RP, et al. Multiple dose study to investigate the safety of UK-427,857 (100 mg or 300 mg) BID for 28 days in healthy males and females. In 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, 14-17 September 2003; Abstract H-874.
51. Kliger Y, Gallo SA, Peisajovich SG, et al. Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage. J Biol Chem 2001; 276: 1391-1397.
52. Matthews TJ, Wild C, Chen CH, et al. Structural rearrangements in the transmembrane glycoprotein after receptor binding. Immunol Rev 1994; 140: 93-104.
53. Wild C, Oas T, McDanal C, et al. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci USA 1992; 89: 10537-10541.
54. Lawless MK, Barney S, Guthrie KI, et al. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41. Biochemistry 1996; 35: 13697-13708.
55. Nagashima KA, Thompson DA, Rosenfield SI, et al. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 2001; 183: 1121-1125.
56. Pine PS, Weaver JL, Oravecz T, et al. A semiautomated fluorescence-based cell-to-cell fusion assay for gp120-gp41 and CD4 expressing cells. Exp Cell Res 1998; 240: 49-57.
57. Greenberg ML, McDanal CB, Stanfield-Oakley SA, et al. Virus sensitivity to T-20 and T-1249 is independent of coreceptor usage. In 8th Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 4-8 February 2001; Abstract 473.
58. Heil M, Decker JM, Chen J, et al. Analysis of patient-derived HIV-1 isolates suggests a novel mechanism for decreased sensitivity to inhibition by enfuvirtide and T-649. In 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, France, 13-16 July 2003; Abstract 801.
59. Labrosse B, Labernardiere JL, Dam E, et al. Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors. J Virol 2003; 77: 1610-1613.
60. Derdeyn CA, Decker JM, Sfakianos JN, et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000; 74: 8358-8367.
61. Derdeyn CA, Decker JM, Sfakianos JN, et al. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol 2001; 75: 8605-8614.
62. Whitcomb JM, Huang W, Fransen S, et al. Analysis of baseline enfuvirtide (T20) susceptibility and coreceptor tropism in two Phase III study populations. In 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA, 10-14 February 2003; Abstract 557.
63. Stanfield-Oakley SA, Jeffrey J, McDanal CB, et al. Determinants of susceptibility to enfuvirtide map to gp41 in enfuvirtide-naive HIV-1. In XII Intenational HIV Drug Resistance Workshop, Los Cabos, Mexico, 10-14 June 2003; Abstract 56.
64. Greenberg ML, Melby T, Sista P, et al. Baseline and on-treatment susceptibility to enfuvirtide seen in TORO 1 and TORO 2 through 24 weeks. In 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA, 10-14 February 2003; Abstract 141.
65. Sista P, Melby T, Dhingra U, et al. The fusion inhibitors T-20 and T-1249 demonstrate potent in vitro antiviral activity against clade B HIV-1 isolates resistant to reverse transcriptase and protease inhibitors and non-B clades. In 5th International Workshop on HIV Drug Resistance and Treatment Strategies, Scottsdale, USA, 4-8 June 2001; Abstract 2.
66. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998; 4: 1302-1307.
67. Kilby JM, Lalezari JP, Eron JJ, et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002; 18: 685-693.
68. Lalezari JP, Eron JJ, Carlson M, et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 2003; 17: 691-698.
69. Piketty C, Race E, Castiel P, et al. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS 1999; 13: F71-F77.
70. Lalezari J, DeJesus E, Northfelt D, et al. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir, and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther 2003; 8: 279-287.
71. Wheeler DA, Lalezari JP, Kilby JM, et al. Safety, tolerability and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients. J Clin Virol 2004; 30: 183-190.
72. Zhang X, Nieforth K, Lang J, et al. Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition. Clin Pharmacol Ther 2002; 72: 10-19.
73. Lalezari JP, Patel IH, Zhang X, et al. Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients. J Clin Virol 2003; 28: 217-222.
74. Bellibas SE, Siddique Z, Dorr A, et al. Pharmacokinetics of enfuvirtide in pediatric HIV infected patients receiving combination therapy. In 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, 13-16 July 2003; Abstract 841.
75. Church JA, Cunningham C, Hughes M, et al. Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. Pediatr Infect Dis J 2002; 21: 653-659.
76. Cunningham C, Church J, Hughes M, et al. Chronic subcutaneous T-20 (enfuvirtide) in HIV infected children: 48 week outcome. In 40th Annual Meeting of IDSA (Infectious Diseases Society of America), Chicago, USA, 24-27 October 2002; Abstract 441.
77. Zhang X, Lalezari JP, Badley AD, et al. Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther 2004; 75: 558-568.
78. Boyd MA, Zhang X, Dorr A, et al. Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide. J Clin Pharmacol 2003; 43: 1382-1391.
79. Ruxrungtham K, Boyd M, Bellibas SE, et al. Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients. J Clin Pharmacol 2004; 44(7): 793-803.
80. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348: 2175-2185.
81. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant human immunodeficiency virus type 1 in Europe and Australia. N Engl J Med 2003; 348: 2186-2195.
82. Katlama C, Arastéh K, Clotet B, et al. Enfuvirtide TORO studies: 48 week results confirm 24 week findings. In 2nd International AIDS Society Meeting, Paris, France, 13-16 July 2003; Abstract LB2.
83. Sista P, Melby T, Greenberg ML, et al. Subgroup analysis of baseline (BL) susceptibility and early virological response to enfuvirtide in the combined TORO studies. In XII International HIV Drug Resistance Workshop, Los Cabos, Mexico, 10-14 June 2003; Abstract 55.
84. Lalezari J, Henry K, O'Hearn M, et al. Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone: week 24 response among categories of treatment experience and baseline (BL) HIV antiretroviral (ARV) resistance. In 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA, 27-30 September 2002; Abstract 3232.
85. Lange J, Lazzarin A, Clotet B, et al. Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone: week 24 response among categories of baseline (BL) demographics, treatment experience, and HIV anti-retroviral (ARV) resistance. In 6th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 17-21 November 2002; Abstract PL14.3.
86. Montaner J, DeMasi R, Delehanty J, et al. Analysis of virological response of enfuvirtide in TORO: implications for patient management. In 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, 13-16 July 2003; Abstract 116.
87. Walmsley S, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in subgroups of patients through 48 weeks of therapy in the TORO trials. In 9th European AIDS Conference, Warsaw, Poland, 25-29 October 2003; Abstract 7.3/15.
88. Trottier B, Arastéh K, Henry K, et al. Durability of response of enfuvirtide through 48 weeks in the TORO trials. In 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, 14-17 September 2003; Abstract H-835.
89. Drobnes C, Fang L, Nelson E, et al. Tolerability of enfuvirtide (T-20) during chronic therapy in Phase II trials. In 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA, 27-30 September 2002; Abstract H-171.
90. Eron J, Delfraissy J-F, Kuritzkes DR, et al. Safety of enfuvirtide (ENF) through 48 weeks of therapy in the TORO trials. In 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, 14-17 September 2003; Abstract H-836.
91. Boschini A, Smacchia C, Di Fine M, et al. Community-acquired pneumonia in a cohort of former injection drug users with and without human immunodeficiency virus infection: incidence, etiologies, and clinical aspects. Clin Infect Dis 1996; 23: 107-113.
92. Sullivan JH, Moore RD, Keruly JC, et al. Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. Am J Respir Crit Care Med 2000; 162: 64-67.
93. de Gaetano DK, Bertagnolio S, Tumbarello M, et al. Effect of highly active antiretroviral therapy on the incidence of bacterial pneumonia in HIV-infected subjects. Int J Antimicrob Agents 2000; 16: 357-360.
94. Hirschtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med 1995; 333: 845-851.
95. Piliero PJ, Fish DG, Preston S, et al. Guillain-Barre syndrome associated with immune reconstitution. Clin Infect Dis 2003; 36: e111-e114.
96. de Rosny E, Vassell R, Wingfield PT, et al. Peptides corresponding to the heptad repeat motifs in the transmembrane protein (gp41) of human immunodeficiency virus type 1 elicit antibodies to receptor-activated conformations of the envelope glycoprotein. J Virol 2001; 75: 8859-8863.
97. DiMassimo B, Milam D, Rusnak P, et al. Effects of peptide-induced humoral responses and preexisting antibodies in nonhuman primates and HIV-infected patients following chronic administration of T-20. In 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA, 30 January-2 February 2000; Abstract 502.
98. Walmsley S, Henry K, Katlama C, et al. Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide. J Infect Dis 2003; 188: 1827-1833.
99. Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 1998; 72: 986-993.
100. Mink M, Greenberg ML, Mosier S, et al. Impact of HIV-1 gp41 amino acid substitutions (positions 36-45) on susceptibility to T-20 (enfuvirtide) in vitro: Analysis of primary virus isolates recovered from patients during chronic enfuvirtide treatment and site directed mutants in NL4-3. In XI International HIV Drug Resistance Workshop, Seville, Spain, 2-5 July 2002; Abstract 22.
101. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46: 1896-1905.
102. Mink M, Janumpalli S, Davison D, et al. Correlation of gp41 binding and antiviral potencies of the fusion inhibitor T-20 using clinical trial isolate-derived sequences. In 8th Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 4-8 February 2001; Abstract 474.
103. Wheat LJ, Lalezari J, Kilby JM, et al. A week 48 assessment of high strength T-20 formulations in multi-class experienced patients. In 9th Conference on Retroviruses and Opportunistic Infections, Seattle, USA, 24-28 February 2002; Abstract 417-W.
104. Greenberg ML, Sista P, Miralles G, et al. Enfuvirtide (T-20) and T-1249 resistance: observations from Phase II clinical trials of enfuvirtide in combination with oral antiretrovirals (ARVs) and a Phase I/II dose-ranging monotherapy trial of T-1249. In XI International HIV Drug Resistance Workshop, Seville, Spain, 2-5 July 2002; Abstract 128.
105. Sista P, Melby T, Greenberg ML, et al. Characterization of baseline and treatment-emergent resistance to T-20 (enfuvirtide) observed in phase II clinical trials: substitutions in gp41 amino acids 36-45 and enfuvirtide susceptibility of virus isolates. In XI International HIV Drug Resistance Workshop, Seville, Spain, 2-5 July 2002; Abstract 21.
106. Xu L, Pozniak A, Wildfire A, et al. Evolution of HR1 and HR2 mutations in HIV-1 gp41 associated with long-term enfuvirtide therapy. In 11th Conference on Retroviruses and Oppoprtunistic Infections, San Francisco, USA, 8-11 February 2004; Abstract 659.
107. Chan DC, Pass D, Berger JM, et al. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997; 89: 263-273.
108. Green J, Kleinman L, Ciesla G, et al. Subcutaneous injection survey: psychometric evaluation of a treatment satisfaction instrument associated with a novel HIV medication. HIV Clin Trials 2002; 3: 387-395.
109. Cohen C, Hellinger J, Johnson M, et al. Patient acceptance of self-injected enfuvirtide at 8 and 24 weeks. HIV Clin Trials 2003; 4: 347-357.